Meds Rarely Offered for COVID-19 Patients at High Risk for Progression
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 25, 2024 -- Many patients with mild-to-moderate COVID-19 infection at high risk for progression are not offered antiviral medication treatment, according to research published in the Jan. 25 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Paul A. Monach, M.D., Ph.D., from the VA Boston Cooperative Studies Program, and colleagues ascertained reasons for underuse of antiviral medications to prevent severe COVID-19. One hundred ten Veterans Health Administration patients with mild-to-moderate infection at high risk for progression due to underlying conditions who did not receive antiviral medications were assessed.
All the patients had received the COVID-19 vaccine; 20.0 and 80.0 percent were offered treatment but declined and were not offered treatment, respectively. The researchers found that among the patients who were not offered treatment, provider reasons included symptom duration of more than five days, concern regarding possible drug interactions, and absence of symptoms (22.7, 5.7, and 22.7 percent, respectively); no reason other than mild symptoms was given for 48.9 percent of these patients (43 of 88 patients). For 24 of the 43 patients (55.8 percent), follow-up was limited to telephone calls to report test results and ask about symptom evolution; there were no reports of treatment being offered.
"Education of providers, patients, and staff members tasked with follow-up calls might increase use of antiviral medications for mild-to-moderate COVID-19, especially if combined with advance planning for possible antiviral treatment at the time of testing or earlier," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted January 2024
Further Support and Information on COVID-19
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
Cannabis Use Tied to Risk of COVID-19 Hospitalizations, ICU Admissions
TUESDAY, June 25, 2024 -- Current cannabis use may be an independent risk factor for COVID-19–related complications, according to a study published online June 21...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.